Fig. 3From: Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ studyCorrelation between eosinophil count at screening and the number of COPD exacerbations during the study in the LABA/LAMA FDC and triple therapy groups (per protocol set). The inset graphs display the same data as the main graphs, but with the x-axes rescaled. LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, FDC fixed-dose combination, COPD chronic obstructive pulmonary diseaseBack to article page